Enterostatin inhibition of dietary fat intake is dependent on CCK-A receptors.
Enterostatin, a pentapeptide released from the exocrine pancreas and gastrointestinal tract, selectively inhibits fat intake through activation of an afferent vagal signaling pathway. This study investigated if the effects of enterostatin were mediated through a CCK-dependent pathway. The series of in vivo and in vitro experiments included studies of 1) the feeding effect of peripheral enterostatin on Otsuka Long Evans Tokushima Fatty (OLETF) rats lacking CCK-A receptors, 2) the effect of CCK-8S on the intake of a two-choice high-fat (HF)/low-fat (LF) diet, 3) the effects of peripheral or central injection of the CCK-A receptor antagonist lorglumide on the feeding inhibition induced by either central or peripheral enterostatin, and 4) the ability of enterostatin to displace CCK binding in a 3T3 cell line expressing CCK-A receptor gene and in rat brain sections. The results showed that OLTEF rats did not respond to enterostatin (300 microg/kg ip) in contrast to the 23% reduction in intake of HF diet in Long Evans Tokushima Otsuka (LETO) control rats. CCK (1 microg/kg ip) decreased the intake of the HF diet in a two-choice diet regime with a compensatory increase in intake of the LF diet. Peripheral injection of lorglumide (300 microg/kg) blocked the feeding inhibition induced by either near-celiac arterial or intracerebroventricular enterostatin, whereas intracerebroventricular lorglumide (5 nmol icv) only blocked the response to intracerebroventricular enterostatin but not to arterial enterostatin. Enterostatin did not bind on CCK-A receptors because neither enterostatin nor its analogs VPDPR and beta-casomorphin displaced [3H]L-364,718 from CCK-A receptors expressed in 3T3 cells or the binding of 125I-CCK-8S from rat brain sections. The data suggest that both the peripheral and central responses to enterostatin are mediated through or dependent on peripheral and central CCK-A receptors.
Lin
Ling
L
Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA. linl@pbrc.edu
Thomas
Sonjya R
SR
Kilroy
Gail
G
Schwartz
Gary J
GJ
York
David A
DA
D016475:3T3 Cells; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003089:Colipases / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D004041:Dietary Fats / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004792:Enzyme Precursors; D005247:Feeding Behavior / Q000187:drug effects*; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D051379:Mice; D011377:Proglumide / Q000031:analogs & derivatives* / Q000494:pharmacology; D011498:Protein Precursors / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000235:genetics / Q000378:metabolism*
D003089:Colipases; D004041:Dietary Fats; D004792:Enzyme Precursors; D011498:Protein Precursors; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; C037107:procolipase; D011377:Proglumide; C048181:lorglumide